Anticardiac antibodies in patients with severe and moderate COVID-19 (correlations with the clinical performance and prognosis)
Open Access
- 5 December 2020
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (11), 4054
- https://doi.org/10.15829/29/1560-4071-2020-4054
Abstract
The level and significance of anticardiac antibodies (ACA) in patients with COVID-19 infection have not yet been studied.Aim. To assess the level of various ACA in patients with severe and moderate COVID-19 infection and to identify the correlation of antibody profile with the clinical performance and prognosis.Material and methods. The study included 86 (38 women and 48 men) patients aged 20-90 years (60,2±16,6 years) who were hospitalized for moderate and severe COVID-19 infection in April-June 2020. Nasopharyngeal swab confirmed the disease in 59,3% of patients. In addition to the standard examination, electrocardiography and chest scan, level of antinuclear antibodies (ANA), antiendothelial cell antibodies (AECA), anti-cardiomyocyte antibodies, antibodies to anti-smooth muscles (ASMA) and cardiac conduction system fibers. Echocardiography was performed in 17 patients. Mean length of stay was 14 [12; 18] days. Death was considered as the primary endpoint.Results. Prevalence of heart disease and symptoms (including hypertension and coronary artery disease) was 45,3%. The manifestations of coronavirus heart damage include arrhythmias (supraventricular premature beats, 3,6%; atrial fibrillation, 9,3%), heart failure (9,3%), low QRS voltage (11,4%), repolarization abnormalities (41,9%), pericardial effusion (30%). An increase in troponin levels was observed in low number of patients. All types of cardiovascular disease correlated with the maximum D-dimer level (AUC, 0,752, pConclusion. An increase in ACA titers was detected in 73,5% of patients, correlated with mortality, in most cases reflects the general activity and severity of the disease and can be regarded as part of response in COVID-19. At the same time, a direct correlation with signs of myocardial damage, the presence and volume of pericardial effusion confirms the direct role of ACA in the development of myopericarditis.Keywords
This publication has 31 references indexed in Scilit:
- The complement system in COVID-19: friend and foe?JCI Insight, 2020
- Miocarditis in Patients with COVID-19 Confirmed by ImmunohistochemicalKardiologiia, 2020
- Case Report: Death due to COVID-19 in Three BrothersThe American Journal of Tropical Medicine and Hygiene, 2020
- Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease‐2019 (COVID‐19)HLA, 2020
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCell Host & Microbe, 2020
- Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike proteinJournal of Medical Virology, 2020
- Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?Autoimmunity Reviews, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020